Adil Doganay Duru

Company: Glycostem Therapeutics

Job title: Director of BD

Seminars:

Discussing Strategies to Target & Overcome the Tumor Microenvironment 2:00 pm

Understanding HLA-G and HLA-E mechanisms employed by tumors to suppress NK cells Discussing armoring approaches like receptor modifications and expression of membrane bound cytokinesRead more

day: Day 2 - Track A - PM

Industry Leader’s Fireside Chat: Discussing Present Advancements & Challenges in the Natural Killer Space to Envision the Future of NK Therapy 8:30 am

Discussing key advancements in the NK space to highlight the therapeutic potential of NK biology Sharing the latest findings in NK therapy and what this means for this field What are the biggest hurdles in this space that still need to be overcome?Read more

day: Day 1 AM

Panel Discussion: Exploring Current & Future Opportunities in Entering the Autoimmune Field as an NK Developer 9:00 am

What makes NK applications to the autoimmune space so exciting? Discussing recent advancements that showcase the promise of NK based therapy in autoimmune disease  Evaluating the main hurdles in expanding NKs to the autoimmune space Why is there more funding in autoimmunity than oncology?Read more

day: Pre-Conference Focus Day

Panel Discussion: Evaluating NK Treatment Regiments in Autoimmune Patients to Maximize Treatment Outcomes 10:30 am

Discussing patient treatment regiments and pre-treatment procedures in an autoimmune setting Do the same measures such as lymphodepletion need to be applied to autoimmune patients? What dosing regiment may be most beneficial for autoimmune patients?  Is it feasible to dose autoimmune patients several times?Read more

day: Pre-Conference Focus Day